Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer

• 主要な著者: Wenjie Liu (著者), Gengwei Huo (著者), Peng Chen (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2024-02-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

BackgroundThe ALTA-1 L trial and EXP-3B arm of NCT01970865 trial found that both brigatinib and lorlatinib showed durable and robust responses in treating ALK-positive non-small cell lung cancer (NSCLC) patients. However, brigatinib and lorlatinib treatments are costly and need indefinite administra...